Cerebrospinal Fluid Neurofilaments Light-Chain Differentiate Patients Affected by Alzheimer's Disease with Different Rate of Progression (RoP): A Preliminary Study
- PMID: 39451975
- PMCID: PMC11505946
- DOI: 10.3390/brainsci14100960
Cerebrospinal Fluid Neurofilaments Light-Chain Differentiate Patients Affected by Alzheimer's Disease with Different Rate of Progression (RoP): A Preliminary Study
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia. One major challenge for clinicians is accurately assessing the rate of disease progression (RoP) early in the diagnostic process, which is crucial for patient management and clinical trial stratification. This study evaluated the role of cerebrospinal fluid biomarkers-Aβ42, t-Tau, pTau, Neurogranin (Ng), and Neurofilament light-chain (NF-L)-in predicting RoP at the time of AD diagnosis. We included 56 AD patients and monitored cognitive impairment using MMSE scores at diagnosis and during six-month follow-up visits. RoP scores were calculated based on these assessments. Our correlation analyses revealed significant associations between RoP and pTau, Aβ42/Ng ratio, and NF-L levels. When patients were stratified by median RoP values into low-to-moderate (L-M: <2) and upper-moderate (U-M: >2) groups, those in the U-M group had notably higher CSF NF-L levels compared to the L-M group. Logistic regression analysis further demonstrated that elevated CSF NF-L levels were predictive of a faster RoP. These findings highlight the potential of CSF NF-L as a prognostic biomarker for rapid disease progression in AD. By identifying patients at risk for accelerated cognitive decline, CSF NF-L could significantly enhance early intervention strategies and improve patient management in clinical settings.
Keywords: Alzheimer’s disease; CSF; biomarkers; dementia; neurofilaments; progression.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.J Neural Transm (Vienna). 2016 Dec;123(12):1443-1447. doi: 10.1007/s00702-016-1597-3. Epub 2016 Aug 16. J Neural Transm (Vienna). 2016. PMID: 27531278
-
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6. J Prev Alzheimers Dis. 2020. PMID: 32920628 Clinical Trial.
-
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.Front Neurol. 2020 Mar 6;11:149. doi: 10.3389/fneur.2020.00149. eCollection 2020. Front Neurol. 2020. PMID: 32210906 Free PMC article.
-
The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis.Ageing Res Rev. 2021 Dec;72:101491. doi: 10.1016/j.arr.2021.101491. Epub 2021 Oct 21. Ageing Res Rev. 2021. PMID: 34688925 Review.
-
A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.Neurol Ther. 2017 Jul;6(Suppl 1):15-24. doi: 10.1007/s40120-017-0073-9. Epub 2017 Jul 21. Neurol Ther. 2017. PMID: 28733960 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources